Article Text

Download PDFPDF
Management and Prognosis of Borderline Ovarian Brenner Tumors
  1. Catherine Uzan, MD, PhD*,,
  2. Marion Dufeu-Lefebvre, MD*,
  3. Raffaele Fauvet, MD, PhD,§,
  4. Sebastien Gouy, MD*,
  5. Pierre Duvillard, MD,
  6. Emile Darai, MD, PhD,# and
  7. Philippe Morice, MD, PhD*,**
  1. *Department of Gynecologic Surgery and
  2. Unit INSERM U 10–30, Institut Gustave Roussy, Villejuif;
  3. Department of Obstetrics and Gynecology, CHU Amiens;
  4. §INSERM ERI-12, Université de Picardie JulesVernes, Amiens;
  5. Department of Pathology, Institut Gustave Roussy, Villejuif;
  6. Department of Obstetrics and Gynecology, Hopital Tenon, Paris;
  7. #Universite Pierre et Marie Curie (Paris VI), Paris; and
  8. **Université Paris-Sud (Paris XI), Le Kremlin Bicetre, France.
  1. Address correspondence and reprint requests to Philippe Morice, MD, PhD, Service de Chirurgie Gynécologique, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. E-mail: morice{at}igr.fr.

Abstract

Objective The borderline ovarian Brenner tumor (BOBT) of the ovary is a rare tumor, and fewer than 25 cases have been reported in the literature. The aim of this study was to determine the prognosis of a series of BOBT collected in 2 reference centers.

Methods A retrospective review of patients with BOBT treated or referred to our institutions. A centralized histological review by a reference pathologist and data on the clinical characteristics, management, and outcomes of patients were required for inclusion.

Results Ten patients were identified between 2000 and 2010. The median age of patients was 69 years (range, 52–84 years). Eight patients had pure BOBT and 2 had mixed histotype (mucinous and Brenner tumor). All patients had unilateral tumor and a stage I disease. No case of stromal microinvasion or intraepithelial carcinoma was observed. Among 5 patients with data on the follow-up, 1 lethal recurrence (50 months after initial surgery) was observed (the first reported in the literature).

Conclusions During the management of BOBT, peritoneal staging surgery is not required because all patients reported in the present series (and all but one in the literature) had stage I disease. One recurrence had occurred in this retrospective series. Nevertheless, among 35 cases (including those in the present study) reported in the literature with outcomes, this tumor carries a good prognosis. The power of this conclusion is, however, limited because of the relatively small number of patients studied (but this is a rare entity) and the short follow-up period.

  • Borderline tumor
  • Brenner tumor
  • Ovarian tumor
  • Recurrence
  • Prognosis
  • Survival

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.